Literature DB >> 19729604

Level of macrophage uPA expression is an important determinant of atherosclerotic lesion growth in Apoe-/- mice.

Ranjini Krishnan1, Michal Kremen, Jie Hong Hu, Isaac Emery, Stephen D Farris, Katherine I Slezicki, Talyn Chu, Liang Du, Helén L Dichek, David A Dichek.   

Abstract

OBJECTIVE: Enhanced plasminogen activation, mediated by overexpression of urokinase-type plasminogen activator (uPA), accelerates atherosclerosis in apolipoprotein E-null mice. However, the mechanisms through which uPA acts remain unclear. In addition, although elevated uPA expression can accelerate murine atherosclerosis, there is not yet any evidence that decreased uPA expression would retard atherosclerosis. METHODS AND
RESULTS: We used a bone marrow transplant (BMT) approach and apolipoprotein E-deficient (Apoe(-/-)) mice to investigate cellular mechanisms of uPA-accelerated atherosclerosis, aortic dilation, and sudden death. We also used BMT to determine whether postnatal loss of uPA expression in macrophages retards atherosclerosis. BMT from uPA-overexpressing mice yielded recipients with macrophage-specific uPA overexpression; whereas BMT from uPA knockout mice yielded recipients with macrophage-specific loss of uPA expression. Recipients of uPA-overexpressing BM acquired all the vascular phenotypes (accelerated atherosclerosis, aortic medial destruction and dilation, severe coronary stenoses) as well as the sudden death phenotype of uPA-overexpressing mice. Moreover, fat-fed 37-week-old recipients of uPA-null BM had significantly less atherosclerosis than recipients of uPA wild-type marrow (40% less aortic surface lesion area; P=0.03).
CONCLUSIONS: The level of uPA expression by macrophages-over a broad range-is an important determinant of atherosclerotic lesion growth in Apoe(-/-) mice.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19729604      PMCID: PMC2766014          DOI: 10.1161/ATVBAHA.109.195529

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  30 in total

1.  Co-localization of fibrinolytic activators and inhibitors with macrophages in atherosclerotic vessels.

Authors:  M Falkenberg; T Björnheden; P Lindnér; B Risberg
Journal:  Cardiovasc Pathol       Date:  1998 Jul-Aug       Impact factor: 2.185

2.  Fibrinolytic activation markers predict myocardial infarction in the elderly. The Cardiovascular Health Study.

Authors:  M Cushman; R N Lemaitre; L H Kuller; B M Psaty; E M Macy; A R Sharrett; R P Tracy
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-03       Impact factor: 8.311

3.  Relationship of plasmin generation to cardiovascular disease risk factors in elderly men and women.

Authors:  P A Sakkinen; M Cushman; B M Psaty; B Rodriguez; R Boineau; L H Kuller; R P Tracy
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-03       Impact factor: 8.311

4.  ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree.

Authors:  Y Nakashima; A S Plump; E W Raines; J L Breslow; R Ross
Journal:  Arterioscler Thromb       Date:  1994-01

Review 5.  The functions of plasminogen in cardiovascular disease.

Authors:  Edward F Plow; Jane Hoover-Plow
Journal:  Trends Cardiovasc Med       Date:  2004-07       Impact factor: 6.677

6.  Lack of urokinase plasminogen activator promotes progression and instability of atherosclerotic lesions in apolipoprotein E-knockout mice.

Authors:  Claudia Dellas; Carmen Schremmer; Gerd Hasenfuss; Stavros V Konstantinides; Katrin Schäfer
Journal:  Thromb Haemost       Date:  2007-07       Impact factor: 5.249

Review 7.  Novel aspects and new roles for the serine protease plasmin.

Authors:  T Syrovets; Th Simmet
Journal:  Cell Mol Life Sci       Date:  2004-04       Impact factor: 9.261

8.  Macrophage-targeted overexpression of urokinase causes accelerated atherosclerosis, coronary artery occlusions, and premature death.

Authors:  Aaron E Cozen; Hideaki Moriwaki; Michal Kremen; Mary Beth DeYoung; Helén L Dichek; Katherine I Slezicki; Stephen G Young; Murielle Véniant; David A Dichek
Journal:  Circulation       Date:  2004-04-19       Impact factor: 29.690

9.  Physiological consequences of loss of plasminogen activator gene function in mice.

Authors:  P Carmeliet; L Schoonjans; L Kieckens; B Ream; J Degen; R Bronson; R De Vos; J J van den Oord; D Collen; R C Mulligan
Journal:  Nature       Date:  1994-03-31       Impact factor: 49.962

10.  Overexpression of urokinase by macrophages or deficiency of plasminogen activator inhibitor type 1 causes cardiac fibrosis in mice.

Authors:  Hideaki Moriwaki; April Stempien-Otero; Michal Kremen; Aaron E Cozen; David A Dichek
Journal:  Circ Res       Date:  2004-08-05       Impact factor: 17.367

View more
  9 in total

1.  Overexpression of urokinase by plaque macrophages causes histological features of plaque rupture and increases vascular matrix metalloproteinase activity in aged apolipoprotein e-null mice.

Authors:  Jie Hong Hu; Liang Du; Talyn Chu; Goro Otsuka; Nagadhara Dronadula; Mia Jaffe; Sean E Gill; William C Parks; David A Dichek
Journal:  Circulation       Date:  2010-03-29       Impact factor: 29.690

2.  Macrophage-specific expression of urokinase-type plasminogen activator promotes skeletal muscle regeneration.

Authors:  Margaret L Novak; Scott C Bryer; Ming Cheng; Mai-Huong Nguyen; Kevin L Conley; Andrew K Cunningham; Bing Xue; Thomas H Sisson; Jae-Sung You; Troy A Hornberger; Timothy J Koh
Journal:  J Immunol       Date:  2011-06-27       Impact factor: 5.422

3.  Urokinase-type plasminogen activator deficiency in bone marrow-derived cells augments rupture of angiotensin II-induced abdominal aortic aneurysms.

Authors:  Haruhito A Uchida; Aruna Poduri; Venkateswaran Subramanian; Lisa A Cassis; Alan Daugherty
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-08-25       Impact factor: 8.311

4.  Mechanisms of urokinase plasminogen activator (uPA)-mediated atherosclerosis: role of the uPA receptor and S100A8/A9 proteins.

Authors:  Stephen D Farris; Jie Hong Hu; Ranjini Krishnan; Isaac Emery; Talyn Chu; Liang Du; Michal Kremen; Helén L Dichek; Elizabeth Gold; Stephen A Ramsey; David A Dichek
Journal:  J Biol Chem       Date:  2011-05-02       Impact factor: 5.157

5.  Reduction of mouse atherosclerosis by urokinase inhibition or with a limited-spectrum matrix metalloproteinase inhibitor.

Authors:  Jie Hong Hu; Phanith Touch; Jingwan Zhang; Hao Wei; Shihui Liu; Ida K Lund; Gunilla Høyer-Hansen; David A Dichek
Journal:  Cardiovasc Res       Date:  2015-01-23       Impact factor: 10.787

6.  Plasmin promotes foam cell formation by increasing macrophage catabolism of aggregated low-density lipoprotein.

Authors:  Abigail S Haka; Inna Grosheva; Rajesh K Singh; Frederick R Maxfield
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-05-23       Impact factor: 8.311

Review 7.  Renal biopsy: use of biomarkers as a tool for the diagnosis of focal segmental glomerulosclerosis.

Authors:  Crislaine Aparecida da Silva; Mariana Molinar Mauad Cintra; Eliângela de Castro Côbo; Marcos Vinícius da Silva; Fabiano Bichuette Custódio; Rosana Rosa Miranda Corrêa; Lúcio Roberto Castellano; Marlene Antônia dos Reis; Juliana Reis Machado
Journal:  Dis Markers       Date:  2014-02-25       Impact factor: 3.434

8.  PAI-1 (Plasminogen Activator Inhibitor-1) Expression Renders Alternatively Activated Human Macrophages Proteolytically Quiescent.

Authors:  Philipp J Hohensinner; Johanna Baumgartner; Julia B Kral-Pointner; Pavel Uhrin; Benjamin Ebenbauer; Barbara Thaler; Konstantin Doberer; Stefan Stojkovic; Svitlana Demyanets; Michael B Fischer; Kurt Huber; Gernot Schabbauer; Walter S Speidl; Johann Wojta
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-08-17       Impact factor: 8.311

9.  Genetic-genomic replication to identify candidate mouse atherosclerosis modifier genes.

Authors:  Jeffrey Hsu; Jonathan D Smith
Journal:  J Am Heart Assoc       Date:  2013-01-23       Impact factor: 5.501

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.